In Oct 2007, the FDA introduced that the labeling for all PDE5 inhibitors, which include tadalafil, requires a more popular warning in the possible chance of unexpected hearing reduction as the results of publish-marketing and advertising reviews of short-term deafness related to use of PDE5 inhibit